floxuridine has been researched along with Esophageal Neoplasms in 8 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sensitivity of cancer cells to capecitabine, which is an oral, tumor-selective pre-prodrug of 5-fluorouracil may correlate better to the TP/DPD ratio than to levels of either enzyme alone." | 1.33 | Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry. ( Bacsó, Z; Eliason, JF; Megyeri, A; Shields, A, 2005) |
| "She was diagnosed as having an advanced gastric cancer, which was unresectable because of liver metastasis, esophageal invasion and paraaortic lymph node metastasis." | 1.29 | [Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5'-DFUR combination chemotherapy--a case report]. ( Hoshino, K; Ikeda, H; Kamoshita, N; Kobayashi, J; Koyama, T; Morishita, Y; Nakamura, M; Tanaka, T, 1996) |
| "The authors report a case with esophageal cancer who had undergone a non-curative resection and showed a recurrence." | 1.28 | [A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations]. ( Fujimura, N; Ishida, C; Koyama, S; Maezato, K; Makino, N; Matsukawa, Y; Matsumoto, K; Mizuno, Y; Naitoh, M; Yamamoto, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solomon, N | 1 |
| Mezentsev, D | 2 |
| Reis, I | 1 |
| Lima, M | 3 |
| Rios, J | 2 |
| Avisar, E | 2 |
| Franceschi, D | 3 |
| Livingstone, A | 2 |
| Podolsky, L | 1 |
| Ardalan, B | 3 |
| Megyeri, A | 1 |
| Bacsó, Z | 1 |
| Shields, A | 1 |
| Eliason, JF | 1 |
| Ribeiro, A | 1 |
| Parra, J | 1 |
| Hamilton-Nelson, K | 1 |
| Spector, SA | 1 |
| Livingstone, AS | 1 |
| Bowen-Wells, CP | 1 |
| Sparling, L | 1 |
| Sapp, M | 1 |
| Walker, G | 1 |
| Ganjei-Azar, P | 1 |
| Leichman, CG | 1 |
| Hoshino, K | 1 |
| Nakamura, M | 1 |
| Kamoshita, N | 1 |
| Ikeda, H | 1 |
| Kobayashi, J | 1 |
| Tanaka, T | 1 |
| Koyama, T | 1 |
| Morishita, Y | 1 |
| Mizuno, Y | 1 |
| Makino, N | 1 |
| Matsumoto, K | 1 |
| Fujimura, N | 1 |
| Yamamoto, E | 1 |
| Ishida, C | 1 |
| Koyama, S | 1 |
| Naitoh, M | 1 |
| Maezato, K | 1 |
| Matsukawa, Y | 1 |
| Krakoff, IH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma[NCT00448760] | Phase 2 | 29 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:~Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.~Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions." (NCT00448760)
Timeframe: 8 - 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Single Arm | 72.4 |
(NCT00448760)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Single Arm | 13.6 |
(NCT00448760)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Single Arm | 21.4 |
No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy. (NCT00448760)
Timeframe: 8 - 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Single Arm | 16.7 |
1 review available for floxuridine and Esophageal Neoplasms
| Article | Year |
|---|---|
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm | 1994 |
2 trials available for floxuridine and Esophageal Neoplasms
| Article | Year |
|---|---|
A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2011 |
Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2007 |
5 other studies available for floxuridine and Esophageal Neoplasms
| Article | Year |
|---|---|
Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Dihyd | 2005 |
Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Endoso | 2006 |
[Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5'-DFUR combination chemotherapy--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Esoph | 1996 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
Chemotherapy of gastrointestinal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Esophageal Neoplasms; Floxuridine; Fluorouracil; Gastroint | 1972 |